Remove 2020 Remove Compounding Remove Dosage
article thumbnail

NHS approval of endometriosis therapy Ryeqo enhances patient care: GlobalData

Express Pharma

GlobalDatas report, Endometriosis Market Size and Trend Report, reveals that the endometriosis market size across the seven major markets* (7MM) is expected to achieve a compound annual growth rate of more than 9 per cent during 2020-2030.

Dosage 66
article thumbnail

OSD contract manufacturing market valued at $54.7 billion by 2030

European Pharmaceutical Review

A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 Leading companies in the oral solid dosage market are Catalent, Inc.,

Dosage 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Recommended Medical Reference

RX Note

Adverse Drug Reaction Drug Induced Diseases, 2018 Meyler's Side Effects of Drugs, 2015 Antibiotics The Sanford Guide to Antimicrobial Therapy, 2022 Breastfeeding Briggs' Drugs in Pregnancy and Lactation, 2021 Hale's Medications and Mothers' Milk, 2021 Clinical Practice Applied Therapeutics, 2018 Conn’s Current Therapy, 2022 Current Medical Diagnosis (..)

article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. Brussels; 2020. London: Office of Health Economics; 2020. Available from: [link].

article thumbnail

Extemporaneous Formulation

RX Note

Introduction Despite the shifting of pharmacy focus to pharmaceutical care, the practice of compounding pharmaceutical formulations remains an essential skill for pharmacists. Ora-Blend Ora-Blend is a flavoured oral suspending vehicle used to simplify the process involved in the extemporaneous compounding of oral suspensions.

article thumbnail

Eli Lilly Files Suit Challenging the FDA’s Drug Classification of Retatrutide

Big Molecule Watch

Lilly’s suit marks the third lawsuit against the FDA since 2020 challenging the agency’s decision to classify a product as a drug rather than a biological product. Lilly’s suit marks the third lawsuit against the FDA since 2020 challenging the agency’s decision to classify a product as a drug rather than a biological product.

Dosage 49
article thumbnail

API nitrosamines: method sensitivity issues

European Pharmaceutical Review

pH of a slurry of the solid oral dosage form? Carcinogenicity data was then reviewed for structurally relevant nitrosamines and group-AIs were derived based on the most potent compound within each group. 25 June 2020. EMA/369136/2020. Presented to: Prescription/Non-Prescription Stakeholder Forum November 19, 2020.

Dosage 59